NSE: DIVISLAB | BSE: 532488

Expensive Performer

Download real time

6183.50 107.00 (1.76%)

Near 52W High of ₹6308.50

193.2K NSE+BSE Volume

NSE 14 May, 2025 12:00 PM (IST)

164,152.5

Market Cap

Market Runner Up

0.6

Beta 1Year

Very Low volatility

Board Meeting

The next board meeting for Divi's Laboratories Ltd. is on 17 May 2025 for the purpose of Audited Results & Dividend See details

Divi's Laboratories Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for DIVISLAB, BSE:532488 Divi's Laboratories Ltd.

Divi's Laboratories Ltd.

03 Nov 2017

6183.50

1.76%

Divi's Laboratories

Hold: Divi's Laboratories Ltd.

Target

ICICI Securities Limited

ICICI Securities Ltd | Retail Equity Research Revenues declined 12% YoY to | 890 crore (I-direct estimate: | 959 crore), mainly due to loss of sales and delays of export shipments of...

Divi's Laboratories Ltd. has gained 58.09% in the last 1 Year

Divi's Laboratories Ltd.

02 Nov 2017

6183.50

1.76%

Divi's Laboratories: US FDA clears Unit-2; positives already priced in

Neutral: Divi's Laboratories Ltd.

Target

Motilal Oswal

Divi's Laboratories (DIVI) announced that the US FDA will lift the import alert under clause 66-32 at the Vishakhapatnam-based Unit-2 facility. Exposure to the US market from Unit-2 stands at ~22% of total sales (pre-import alert). This has been one of the fastest resolutions post receipt of the import alert in Mar17. Import alert under clause 99-32 was lifted in Jul-17: In July-17, the US FDA lifted the import alert under clause 99-32 on the company's Unit-2 at Visakhapatnam. The FDA had issued an import alert under clauses 99-32 and 66-40 in March 2017 and a warning letter in May 2017 for the Vishakhapatnam...

Number of FII/FPI investors increased from 826 to 922 in Mar 2025 qtr.

Divi's Laboratories Ltd.

01 Nov 2017

6183.50

1.76%

Divi's Labs (2QFY18): Regulatory hurdles persist. Maintain NEUTRAL

Neutral: Divi's Laboratories Ltd.

HDFC Securities

We maintain NEUTRAL rating on the stock, with a revised TP of Rs 700 (16x Sep-19E). Divis Labs (DIVI) reported a muted performance in 2QFY18. Revenue for the quarter was Rs 8.9bn, (~4% below estimates), a decline of ~11% YoY, with the impact of the import alert continuing to be felt. Supply protocols for a plant under an import alert have resulted in slower output for DIVI. EBITDA came in at ~Rs 2.8bn, a margin of 31.1% (in-line with estimates). However, contrary to our expectations, there continued to be remediation costs during this quarter (~Rs 170mn), adjusted for which, the EBITDA margin would be ~33%, a ~190bps beat. PAT was ~Rs 2bn (down ~8% YoY), ~5% below estimates.

Divi's Laboratories Ltd. is trading above all available SMAs

Divi's Laboratories Ltd.

01 Nov 2017

6183.50

1.76%

Divi's Laboratories: Regulatory issues impact revenues

Neutral: Divi's Laboratories Ltd.

Target

Motilal Oswal

~INR170m related to the import alert at Unit II. PAT of INR2.1b (down ~32% YoY) was ~4% below our estimate. Remediation over at Unit-2: DIVI has already completed remediation for observations highlighted by the USFDA in a re-inspection. Management too has met the USFDA in late Oct-17. The company believes that till the import alert resolution does not happen, the sales run-rate will remain at 2Q levels. Capex plan: DIVI spent ~INR4.5b as capital work in progress till end-FY17 to expand capacity at Unit-1 and 2. The company plans to spend ~INR3.65b in...

Divi's Laboratories Ltd. is trading above all available SMAs

Divi's Laboratories Ltd.

14 Oct 2017, 12:00AM

6183.50

1.76%

Divis Labs

Buy: Divi's Laboratories Ltd.

Sharekhan

Event - USFDA to lift Import Alert 66-40 and close out warning letter: USFDA has informed Divis Laboratories (Divis) that it will be lifting Import Alert 66-40 and close out the warning letter at unit-2 at Vishakhapatnam, which was re-inspected in September 2017 and was issued fresh Form 483 with six observations (the...

Divi's Laboratories Ltd. has gained 58.09% in the last 1 Year

Divi's Laboratories Ltd.

03 Oct 2017

6183.50

1.76%

Company Update:Divis Lab.

Buy: Divi's Laboratories Ltd.

Recommendation Target

Axis Direct

We are positively surprised on fast remediation by Divi's followed by quick USFDA re-inspection. Form 483 observations issued in Dec 16 on Unit 2 facility (under Import Alert) have been confirmed as completed and resolved (EIR awaited) after USFDA re-inspection.

Divi's Laboratories Ltd. is trading above all available SMAs

Divi's Laboratories Ltd.

28 Jul 2017

6183.50

1.76%

Result Update - Divi Lab

Hold: Divi's Laboratories Ltd.

Target

Axis Direct

Q1 revenue declined 19% YoY to Rs 8.2 bn (~14% below estimate) as export shipments were impacted due to setting up of revised protocols as stipulated in the import alert by the USFDA. As per the management, the protocols have now been established; expects normalcy from Q2. Divis guides for flat cc r..

Divi's Laboratories Ltd. is trading above all available SMAs

Divi's Laboratories Ltd.

24 Jul 2017

6183.50

1.76%

Divis Laboratories Ltd Q1FY18 results comment

Results Update: Divi's Laboratories Ltd.

HDFC Securities

Revenue decreased by 23.01% to Rs. 821.2 Cr in Q1FY18 when compared to the previous quarter. Revenue decreased by 23.01% to Rs. 821.2 Cr in Q1FY18 when compared to the previous quarter.

Divi's Laboratories Ltd. is trading above all available SMAs

Divi's Laboratories Ltd.

24 Jul 2017

6183.50

1.76%

Divi's Labs (1QFY18): Weathering tough times. Maintain NEUTRAL

Neutral: Divi's Laboratories Ltd.

Recommendation Target

HDFC Securities

With the recent run-up in the stock price and the inspection at Unit-I looming, we maintain a NEUTRAL rating on the stock, with a revised TP of Rs 680 (16x Jun-19E). We foresee ~2% revenue CAGR over FY17-20E, and ~5% earnings CAGR. With the import alert (IA) on its crucial Unit-II facility coming into force at the end of Mar-17, 1QFY18 was expected to finally reveal the true picture of Divis Labs (DIVI) business as it stands. Significantly, the top-line declined ~19% YoY, EBITDA margin came in at ~30% (vs ~40% in 1QFY17) and PAT was Rs ~1.8bn (down ~42% YoY). Absence of non-exempted products in revenues, coupled with the time taken to establish protocols and procedures required to export the exempted products under the IA, led to this steep decline in the business. Remediation costs at Unit-II and preparations at Unit-I also contributed to the margin decline.

Number of FII/FPI investors increased from 826 to 922 in Mar 2025 qtr.

Is Divi's Laboratories Ltd. worth buying?

745 Votes:

Buy 78.12%

Sell 14.9%

Hold 6.98%

RESEARCH REPORTS

Hold SEE REPORTS >

pdf

Accumulate SEE REPORTS >

pdf